Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

Next Previous
X
Search
Trial Profile

A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Demcizumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Ductal carcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms Yosemite
  • Sponsors OncoMed Pharmaceuticals

    • Most Recent Events

    • 09 Oct 2020 This trial has been discontinued in UK (Global End Date: 08 May 2017), according to European Clinical Trials Database record.
    • 19 Oct 2017 Status changed from active no longer recruiting to completed.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top